Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Sees Market Opening Up In China

Executive Summary

As China’s government raises quality standards for generics, Sandoz views the local market as promising, according to the Novartis division’s head, Richard Francis.

You may also be interested in...



Sandoz Will Consider Local Partnerships In China

As it builds a portfolio in the Chinese market, which is increasingly focused on high-quality products, Sandoz is considering teaming up with local players for certain drugs.

Sandoz’ Unique Chinese Approval Paves The Way For Tender Access

Sandoz says a first-of-its-kind Chinese approval for generic rosuvastatin will open the door for the firm to participate in local tenders.

Autonomous Sandoz Set To Be Tighter And Leaner

With an optimized manufacturing base, a narrower geographic footprint, and a tighter portfolio focus on differentiated biosimilars and hard-to-make generics, Novartis believes a more autonomous Sandoz division can remain an “integral part” of the Swiss group.

Related Content

Topics

UsernamePublicRestriction

Register

GB139931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel